Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

To see complete record on, please visit this link

Id: NCT03156504

Organisation Name: Mayo Clinic

Overal Status: Completed

Start Date: June 1, 2017

Last Update: March 15, 2022

Lead Sponsor: Mayo Clinic

Brief Summary: The purpose of this research study is to find out if the medication known as ketamine can help the symptoms of depression. This drug is approved by the Food and Drug Administration (FDA) but the investigators will use it for a non-FDA approved reason (depression).

  • Major Depression
  • Bipolar I Disorder
  • Bipolar II Disorder
  • Unipolar Depression

Total execution time in seconds: 0.31232309341431